Constellation Pharmaceuticals Inc
Constellation Pharmaceuticals — Investor Presentation (September 2019)
45 slides from Constellation Pharmaceuticals's investor presentation, Sep 24, 2019
Slide 1: Developing Next-Generation Epigenetic Treatments for Cancer Patients
Exhibit 99.1 Developing Next-Generation Epigenetic Treatments for Cancer Patients Corporate Overview September 24, 2019 Stellar Science, Breakthrough MedicineExhibit 99.1 Developing Next-Generation Epigenetic Treatments for Cancer Patients Corporate Overview September 24, 2019 Stellar Science, Break
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the implications of preclinical data and the development stat
Slide 3: Constellation Highlights
Constellation Highlights Three wholly owned clinical programs: CPI-0610 (BET) and CPI-1205 and CPI-0209 (EZH2) CPI-0610 has possible disease-modifying effects in myelofibrosis CPI-1205 has been well tolerated and active in clinical studies in combination with ARS inhibitors in prostate cancer CPI-02
Slide 4: Multiple Near-Term Opportunities for Success
Multiple Near-Term Opportunities for Success Product Candidates Indications Preclinical Phase 1 Phase 2 Phase 3 Milestones BET Inhibitor 2L Myelofibrosis✓ Interim Ph 2 data at ASCO/EHA CPI-0610 MANIFEST Trial 1L Myelofibrosis❑ Additional data update in 4Q19 EZH2 Franchise ✓ Phase 1b data at AACR CPI
Slide 5: Vision for 2019: A Year of Data
Vision for 2019: A Year of Data Transition into a Late-Stage Oncology Development Company with an Exciting Pipeline of Development and Discovery Programs ● Generate positive POC and begin planning for pivotal registration studies with CPI-0610 and CPI-1205 ● Expand our EZH2 franchise by advancing CP
Slide 6: Epigenetics: Instructions for Genetic Code
Epigenetics: Instructions for Genetic Code Focused on Three Distinct Classes That Tumor Microenvironment Chemically Modify Chromatin Writers Erasers Readers Tumor Cells T Cell NK Cell MDSC Target Re-program Immune Transcriptional Cells to Overcome Transcriptional Control to Turn Genes On or Off Netw
Slide 7: CPI-0610
CPI-0610CPI-0610
Slide 8: BET Family of Proteins and Opportunity in Myelofibrosis
BET Family of Proteins Control of Key Immune, Fibrotic, and Oncogenic Pathways Leads to Opportunity in Myelofibrosis (MF) Immune Signaling ● NF-κB target genes Fibrosis ● TGF-β target genes Transcription Factor Enhancer Cancer Genetics BRD4 ● MYC, BCL2 … TSS 8BET Family of Proteins Control of Key Im
Slide 9: In Vivo Support for BET Inhibition Enhancing JAK Inhibition in MF
In Vivo Support for BET Inhibition Enhancing JAK Inhibition in MF BET Inhibitor + Ruxolitinib Led to Synergistic Improved Bone Marrow Fibrosis Score Reduction in Spleen * Vehicle JQ1 (BETi) 1–2+ 1+ * 900 800 700 600 500 * 400 300 200 100 Ruxolitinib Combo 0 1+ 0 Vehicle JQ1 (BETi) Ruxolitinib Combo
Slide 10: Myelofibrosis Patient Journey: Positioning Options for CPI-0610
Myelofibrosis Patient Journey Multiple Positioning Options for CPI-0610 1L: Treatment 2L: Continue on Symptomatic MF with ruxolitinib ruxolitinib CPI-0610 CPI-0610 + Rux Combo Add-On Vision for CPI-0610 Provide Differentiated Diseased Treatment for 2L Bone Marrow Ruxolitinib-Resistant Patients 2L: D
Slide 11: Mechanism of Potential Disease Modification in Myelofibrosis
Mechanism of Potential Disease Modification in Myelofibrosis Reduce Inflammation and Suppress Cells in the Bone Marrow that Drive MF (Megakaryocytes) Cytoplasm JAK/STAT Nucleus Signaling BET Signaling STAT STAT NF-kB Target Genes BETs P P CPI-0610 Pro-Inflammatory Cytokines Differentiation of Myeloi
Slide 12: CPI-0610 is a Potential Best-in-Class BET Inhibitor
CPI-0610 is a Potential Best-in-Class BET Inhibitor ● Potent and selective inhibitor of BET proteins Selected BET Inhibitors with Published Phase 1 Lymphoma Data ● Treated 138 patients in Phase 1 trials of various hematologic malignancies 300 ● Preliminary clinical activity observed: 200 – Potential
Slide 13: Unmet Need for Disease-Modifying Therapy in Four Hallmarks of MF
Working to Meet Unmet Need for a Disease-Modifying Therapy that Impacts All Four Hallmarks of MF Hallmarks of Myelofibrosis Spleen Constitutional Anemia & Transfusion Bone Marrow Volume Symptoms Dependence Fibrosis 2018 Rux WW Sales: ~$2.4B** JAKi’s 2018 Rux WW MF Sales: ~$1.4B*** CPI-0610* * Based
Slide 14: MANIFEST Study Design Overview
MANIFEST Study Design Overview Treatment Study Population Arm / Cohort Cohort 1A: TD ▪No longer on ruxolitinib n = up to 16 CPI-0610 ▪Refractory or intolerant Mono Cohort 1B: Non-TD or ineligible Data Cut as of April 17, 2019 n = up to 25 • 44 patients enrolled Cohort 2A: TD • No patient experienced
Slide 15: Baseline Demographics and Disease Characteristics
Baseline Demographics and Disease Characteristics Cohort 1A Cohort 1B Cohort 2A Cohort 2B Cohort 3 TOTAL Parameter 0610 Mono 0610 Mono 0610 + Rux 0610 + Rux 0610 + Rux (n=44) TD (n=2) Non-TD (n=8) TD (n=16) Non-TD (n=15) JAKi Naïve (n=3) Age Median (range) 68 (67, 69) 70 (46, 80) 72.5 (41, 83) 66 (4
Slide 16: Treatment Duration
Treatment Duration 11-245 ● Total 44 patients enrolled 11-246 11-247 ▪ 39 patients active on treatment; 5 patients 11-248 discontinued 11-252 14-251 14-258 ● Evaluable patients population 11-261 11-264 ▪ Safety: Received C1D1 treatment – n=44 11-265 14-263 14-267 ▪ SVR: Baseline and one post-baselin
Slide 17: Summary of CPI-0610 Data Update from ASCO/EHA 2019
Summary of CPI-0610 Data Update from ASCO/EHA 2019 Hallmarks of Myelofibrosis Spleen Constitutional Anemia & Transfusion Bone Marrow Volume Symptoms Dependence Fibrosis ● 14 of 16 (88%) ● 6 of 11 (55%) of ● Trend of rising HgB ● 6 of 10 (60%) patients achieve patients achieve due to CPI-0610 patient
Slide 18: Best Spleen Volume Reduction
Best Spleen Volume Reduction (n=16) 20 * Cohort 1A (TD - CPI-0610 Mono) ● 14 of 16 evaluable patients had spleen * Cohort 1B (Non-TD - CPI-0610 Mono) volume reductions 10 Cohort 2A (TD - CPI-0610 + Ruxo) Cohort 2B (Non-TD - CPI-0610 + Ruxo) 0 ● Median change of -19.2% -10 ● Spleen volume reduction o
Slide 19: Improvements in Symptoms
Improvements in Symptoms Best % Total Symptom Score (TSS) Improvement Best Patient Global Impression of Change (PGIC) (n=11) Observed (n=16) 4 20 Cohort 1B (Non-TD - CPI-0610 Mono) Cohort 2A (TD - CPI-0610 + Ruxo) 10 Very much worse 7 Cohort 2B (Non-TD - CPI-0610 + Ruxo) Cohort 1A (TD - CPI-0610 Mon
Slide 20: Improvement in Bone Marrow Morphology
Improvement in Bone Marrow Morphology Fibrosis Score Improvements Observed in Monotherapy and Combination Contexts Patient 11-248 Mutation Marrow Fibrosis Grading Reticulin Staining Grading Best % Best Tx Arm / Subject Heavily Pre-Treated, TSS % Cohort ID ≥3 ASXL1 HMR Baseline 24 Wk 48 Wk 72 Wk Base
Slide 21: Two Transfusion-Dependent Patients Converted to Transfusion Independence
Hemoglobin (g/dL) Hemoglobin (g/dL) Two Transfusion-Dependent Patients Converted to Transfusion Independence Patient 11-246: CPI-0610 + Ruxolitinib, Patient 11-252: CPI-0610 + Ruxolitinib, CALR Mutation JAK2, TET2, SRSF2 and U2AF1 Mutations 12 11 400 250 350 10 200 300 10 250 9 150 200 8 100 150 8 1
Slide 22: Improvement in Hemoglobin
Improvement in Hemoglobin Mean Hemoglobin Levels by Treatment Regimen ● Substantial increase in hemoglobin is 3.0 observed in CPI-0610 monotherapy 2.5 patients 2.0 ● With CPI-0610 + ruxolitinib combination, observed improvement 1.5 in hemoglobin is delayed 1.0 ● Patients potentially need to overcome
Slide 23: Hematologic Improvements with CPI-0610 Monotherapy
Hemoglobin (g/dL) Hematologic Improvements with CPI-0610 Monotherapy Patient 11-247, Non-TD, CPI-0610 Monotherapy, ASXL1 and CALR mutations History CPI-0610 Therapy Observations Patient Global Impression Change (PGIC) ● Resistant to Ruxolitinib; ● Monotherapy (225 mg) Very much worse 7 increase in s
Slide 24: Reduction in Pro-inflammatory Cytokine Levels
Reduction in Pro-inflammatory Cytokine Levels ▪ Cytokine reductions observed in MF patients with CPI-0610 monotherapy or combo with ruxolitinib Cohort 1B (Non-TD - CPI-0610 Mono) Cohort 2A (TD - CPI-0610 + Ruxo) Cohort 2B (Non-TD - CPI-0610 + Ruxo) 24 Data cutoff April 17, 2019Reduction in Pro-infla
Slide 25: Treatment Emergent Adverse Events (TEAE)
Treatment Emergent Adverse Events (TEAE) Summary of TEAE by ≥10% Frequency and AESI Treatment Emergent Adverse Event All Grade n=44 (n, %) ≥3 Grade* n=44 (n, %) Blood and Lymphatic System Disorders ● All ≥3 grade TEAE were Anemia 2 (4.5) 2 (4.5) Thrombocytopenia 3 (6.8) 2 (4.5) observed in patients
Slide 26: Effects on Platelet Levels
Effects on Platelet Levels CPI-0610 Monotherapy (n=10) CPI-0610 + Ruxolitinib (n=34) No Patients with Grade 3 Thrombocytopenia 4 of 34 Patients with Grade 3 Thrombocytopenia 1050 1050 900 900 TD TD Non-TD Non-TD 750 750 JAKi Naive 600 600 450 450 300 300 150 150 Gr 3 50 Gr 3 50 25 25 0 0 0 6 12 18 2
Slide 27: Key Takeaways from ASCO/EHA 2019 Update
Key Takeaways from ASCO/EHA 2019 Update Activity across all four hallmarks of myelofibrosis: spleen, symptoms, hematologic function, and bone marrow fibrosis CPI-0610-driven activity in ruxolitinib-resistant patients as monotherapy and as an add-on to ruxolitinib Evidence of early effects on bone ma
Slide 28: Potential Paths to Registration for CPI-0610
Potential Paths to Registration for CPI-0610 † 1L JAKi-Naïve Patients*^ 2L Transfusion-Dependent Patients Anticipated Data By End of 2019 100% 100% Ruxolitinib Spleen Volume Response (SVR%) Momelotinib BAT (89% Rux) 80% 80% • Results from approximately 40 COMFORT-1 SIMPLIFY-1 64.0% 60% 56.0% ruxolit
Slide 29: EZH2 Franchise CPI-1205 and CPI-0209
EZH2 Franchise CPI-1205 and CPI-0209EZH2 Franchise CPI-1205 and CPI-0209
Slide 30: Franchise Approach to Address the Breadth of EZH2 Biology
Franchise Approach to Address the Breadth of EZH2 Biology Polycomb Repressive Complex 2 First Generation CPI-1205 EZH2 Synergy w/ Oncogenic • Potent Drivers • Typical enzyme inhibitor kinetics • Partial target coverage over time • Best for hypersensitive contexts Activating Mutations Tumor Immunity
Slide 31: EZH2 Inhibition Offers Broad Therapeutic Potential
EZH2 Inhibition Offers Broad Therapeutic Potential EZH2 “Writer” Activity Suppresses Gene Transcription Polycomb Repressive Complex 2 CPI-1205 CPI-0209 EZH2 Synergy w/ Oncogenic Prostate Potential Drivers Cancer Add’l st Oppt’y 1 nd for 2 Gen Activating Mutations Lymphoma Gen EZH2i EZH2i Tumor Immun
Slide 32: Model for EZH2 Role in Prostate Cancer
Model for EZH2 Role in Prostate Cancer EZH2 Gene Signature* Predicts Outcomes in Prostate Cancer Coregulators AR AR 1.0 0.9 Synergistically Pro-Tumor EZH2 Enhances AR 0.8 Signaling Signaling 0.7 0.6 0.5 Prostate 0.4 Tumor Growth 0.3 0.2 0 2 4 6 8 10 Time to relapse (years) Yu et al., Cancer Research
Slide 33: EZH2 Synergy with Androgen Receptor Signaling
EZH2 Synergy with Androgen Receptor Signaling (ARS) CPI-1205 Intensifies Gene Expression Effects CPI-1205 is Active as Monotherapy and Synergistic of Enzalutamide in Prostate Cancer Cells* with Enzalutamide in Killing Prostate Cancer Cells Enzalu- CPI- 1.80 Combo tamide 1205 Theoretical concentratio
Slide 34: Current Treatment Paradigm in mCRPC
Current Treatment Paradigm in mCRPC Pre-Metastatic mCRPC Prostate Cancer nd 2 Line rd st 3 Line 1 Line Enzalutamide or Chemotherapy or Abiraterone or Abiraterone Palliative Care Enzalutamide (Poor Activity) CPI-1205 may enhance the activity of ARS inhibitors and reduce need for chemotherapy 34Curren
Slide 35: 2L mCRPC Patients Suffer Poor Response Rate and Short Time to Progression
2L mCRPC Patients Treated with Abiraterone or Enzalutamide Suffer Poor Response Rate and Short Time to Progression* Abiraterone + prednisone Enzalutamide *ASCO 2018 Poster Khalaf, et al. (Kim Chi lab) > PSA30 = 6% > PSA30 = 43% > PSA50 = 4% > PSA50 = 31% > PSA80 = 0% > PSA80 = 10% TTP = 1.6 months T
Slide 36: ProSTAR Trial Design
ProSTAR Trial Design Phase 2 Initiated Phase 1b – Advanced mCRPC Phase 2 – 2L mCRPC Patients Only C CP PII- -1 12 20 05 5 + + A Abi bira rat te erone rone CPI-1205 + Abiraterone** C AP bi I- ra 12 te 0ron 5 + e A bi + ra CP te I-rone* 1205 ( ( (P P Progre rogre rogres s ss s se e ed d d on on on E E
Slide 37: ProSTAR Phase 1b Conclusions
ProSTAR Phase 1b Conclusions* ● CPI-1205 observed to be well-tolerated and clinically active Cycle 1 Cycle 4 ● Recommended Phase 2 dose of 800 mg three times daily Day 1 Day 1 ● Patients’ PSA responses tended to be deeper (e.g., PSA80) and more durable than expected with ARSi alone ● Activity observ
Slide 38: Objective Response by CT Scan
Objective Response by CT Scan Example Patient 2 CPI-1205 + Enzalutamide Baseline: December 2017 February 2018 38Objective Response by CT Scan Example Patient 2 CPI-1205 + Enzalutamide Baseline: December 2017 February 2018 38
Slide 39: Experience with a Compassionate-Use Patient
Experience with a Compassionate-Use Patient Significant PSA Reduction in Heavily Pre-Treated and Refractory Patient Start CPI-1205 + Enzalutamide 3,000 (PSA ~ 2900) 2,500 2,000 1,500 1,000 12 agents prior to CPI-1205, including second-generation 500 androgen inhibitors, chemotherapy, PARP inhibitors
Slide 40: CPI-0209: Second-Generation EZH2 Inhibitor
CPI-0209: Second-Generation EZH2 Inhibitor Once-Daily Treatment Resulted in Rapid and Durable Tumor Regression Bladder Cancer (EZH2 Wild-Type, ARID1A Mutant) – Lymphoma Xenograft – Mutated EZH2 Model More Effective than Cisplatin 2,500 Group 1 Vehicle PO, QD*29 days Group 2 CPI-701532 25 mg/kg PO, Q
Slide 41: Design of Phase 1/2 Clinical Trial of CPI-0209
Design of Phase 1/2 Clinical Trial of CPI-0209 Phase 1 Dose Escalation: Phase 2 Expansion at RP2D*: CPI-0209 Monotherapy CPI-0209 Monotherapy Biomarker-Defined Solid Tumor Populations Advanced, Relapsed Solid Tumors Including Patients w/ ARID1A Mutations ✓Initiated Clear-Cell Ovarian Carcinoma Prima
Slide 42: Discovery Platform Fueling the Pipeline
Discovery Platform Fueling the Pipeline Discovery Programs Targeting Epigenetic Regulators in the Tumor and Immune Microenvironment Tumor Cells Immune Cells Adaptive Innate ● Alter aberrant gene expression within ● Re-program immune cells to overcome cancer cells resistance to cancer immunotherapies
Slide 43: Potential Value Creation Catalysts
Potential Value Creation Catalysts 2018 –Year of Execution 2019 –Year of Data 1H 2018 1H 2019 2H 2019 ✓ Complete crossover financing✓ CPI-1205 – Determine ORIOn-E ✓ CPI-0209 – First patient dosed in safety and recommended Phase 2 Phase 1 ✓ Expand enrollment in ProSTAR dose (RP2D) ❑ CPI-1205 – Provid
Slide 44: Strong Cash Position
Strong Cash Position ● Cash, cash equivalents and marketable $ Millions, 2Q19 2Q18 Except Per-Share Amounts securities as of June 30, 2019, of $98.1 million ● Current cash, cash equivalents and marketable R&D Expenses $16.0 $9.5 securities expected to fund operations until late Q3 2020, including: G
Slide 45: Experienced Management Team, Board, and Scientific Advisors
Experienced Management Team, Board, and Scientific Advisors Management Team Board of Directors Jigar Raythatha Mark Goldsmith, M.D., Tony Evnin, Ph.D., President and CEO Ph.D. (Chairman), Venrock Revolution Medicines Steven Hoerter, Emma Reeve Jigar Raythatha Deciphera SVP & Chief Financial Officer
Constellation Pharmaceuticals — Investor Presentation (September 2019) on 6ix